TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34911566

Group type: EXPERIMENTAL
Intervention: C‐Mill therapy (treadmill-based therapy using gait‐dependent augmented reality)
Number of subjects: 40

Group type: COMPARATOR
Intervention: FALLS program (standard overground program using physical context)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: C‐Mill therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions combined
Number of subjects: 40
Study: 36367144

Group type: EXPERIMENTAL
Intervention: Oral zinc for 15 days
Number of subjects: 470

Group type: COMPARATOR
Intervention: Placebo for 15 days
Number of subjects: 470
Study: 34656194

Group type: EXPERIMENTAL
Intervention: Technical competence
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Global competence
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Technical and global competence
Number of subjects: 38
Study: 33093036

Group type: EXPERIMENTAL
Intervention: HRQoL (EuroQol EQ-5D-3L) after 6 months
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Combined outcome of falls, hospitalisation, institutionalisation and nursing care needs after 6, 9, and 24 months (claims data)
Number of subjects: 502
Study: 35112504

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Oral semaglutide (3, 7, or 14 mg)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701

Group type: COMPARATOR
Intervention: Once-daily subcutaneous liraglutide 0.9 mg
Number of subjects: 701

Group type: COMPARATOR
Intervention: Once-weekly subcutaneous dulaglutide 0.75 mg
Number of subjects: 701
Study: 34484560

Group type: EXPERIMENTAL
Intervention: Dietary valine at 0.59%
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Dietary valine at 0.64%
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Dietary valine at 0.69%
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Dietary valine at 0.74%
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Dietary valine at 0.79%
Number of subjects: 960
Study: 34254577

Group type: EXPERIMENTAL
Intervention: Peer instructors trained by health professionals (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peer instructors trained by their peers (Group B)
Number of subjects: 0
Study: 32580579

Group type: EXPERIMENTAL
Intervention: Infigratinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (gemcitabine and cisplatin)
Number of subjects: 0
Study: 35857356

Group type: EXPERIMENTAL
Intervention: Structured supervised exercise training (EXE)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Motivational counseling (MOT)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard care (CON)
Number of subjects: 220
Study: 33610115

Group type: EXPERIMENTAL
Intervention: Thalidomide + folic acid (group-I)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Hydroxyurea + folic acid (group-II)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Folic acid only (group-III)
Number of subjects: 45
Study: 33296467

Group type: EXPERIMENTAL
Intervention: High-fiber breakfast cereals (>3.5 g/portion)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Low-fiber breakfast cereals (<1.0 g/portion)
Number of subjects: 272
Study: 32407835

Group type: EXPERIMENTAL
Intervention: RPC4046 180 mg
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: RPC4046 360 mg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 35969196

Group type: EXPERIMENTAL
Intervention: Friction group using elastomeric power chains
Number of subjects: 30

Group type: COMPARATOR
Intervention: Frictionless group using T‐loop springs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 33407371

Group type: EXPERIMENTAL
Intervention: Dental intervention combined with dietary and exercise guidance
Number of subjects: 112
Study: 32407947

Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy with allergenic extract
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 35710253

Group type: EXPERIMENTAL
Intervention: Beetroot capsules (500 mg three times a day for 4 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Beetroot plus vitamin C capsules (500 mg three times a day for 4 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo capsules (three times a day for 4 weeks)
Number of subjects: 90
Study: 32987146

Group type: EXPERIMENTAL
Intervention: Temporary intravascular shunts (TIVS)
Number of subjects: 691

Group type: COMPARATOR
Intervention: Management without TIVS (Control)
Number of subjects: 691
Study: 32621736

Group type: EXPERIMENTAL
Intervention: Oral glucose water (10 g of glucose in 100 ml of warm water, 5 ml/kg) 1 hour before surgery
Number of subjects: 344

Group type: COMPARATOR
Intervention: Oral glucose water (10 g of glucose in 100 ml of warm water, 5 ml/kg) 2 hours before surgery
Number of subjects: 344
Study: 35943471

Group type: EXPERIMENTAL
Intervention: Intravenous tirofiban
Number of subjects: 948

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 948
Study: 34264500

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32052740

Group type: EXPERIMENTAL
Intervention: Sleep-disordered breathing (SDB) screening
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Malocclusion (anterior open bite)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Malocclusion (posterior crossbite)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 390
Study: 36564877

Group type: EXPERIMENTAL
Intervention: Regular soy formula intake (≥14 days per month and ≥1350 ml per month)
Number of subjects: 235
Study: 32134394

Group type: EXPERIMENTAL
Intervention: Web-based intervention tailored to individual values and beliefs regarding vaccinations
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 41
Study: 34143996

Group type: EXPERIMENTAL
Intervention: HIVST only
Number of subjects: 4544

Group type: EXPERIMENTAL
Intervention: HIVST plus financial incentive
Number of subjects: 4544

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 4544
Study: 32195640

Group type: EXPERIMENTAL
Intervention: ILIB-100 mW, 660 ± 10 nm, 30 applications in total, divided into 3 stages of 10 applications, 30 min each, daily, with a 20‐day interval between each stage
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control - conventional treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: SILIB - same protocol as ILIB but with equipment switched off
Number of subjects: 30
Study: 33290875

Group type: COMPARATOR
Intervention: Topiramate 0 mg/day + Phentermine 0 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day + Phentermine 15 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day + Phentermine 30 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day + Phentermine 15 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day + Phentermine 30 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Topiramate and Phentermine combined
Number of subjects: 31
Study: 32175638

Group type: EXPERIMENTAL
Intervention: Mechanical compression using the Cirvo device
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pneumatic compression using VenaFlow system
Number of subjects: 15

Group type: COMPARATOR
Intervention: Manual calf compression
Number of subjects: 15
Study: 37698371

Group type: EXPERIMENTAL
Intervention: CYP2D6-genotype-guided opioid selection
Number of subjects: 85

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 85
Study: 33459908

Group type: EXPERIMENTAL
Intervention: First-line treatment in PLA2R-positive patients
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: THSD7A-positive MN treatment
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: PLA2R-positive MN
Number of subjects: 201

Group type: COMPARATOR
Intervention: PLA2R-negative MN
Number of subjects: 201
Study: 32942730

Group type: EXPERIMENTAL
Intervention: DAid smart shirt system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 0
Study: 35400993

Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus (PIEB) 6 mL·h‐1 of 0.1% ropivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI) 6 mL·h‐1 of 0.1% ropivacaine
Number of subjects: 120
Study: 33977775

Group type: EXPERIMENTAL
Intervention: Emotional intelligence skills training (4 sessions)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 32358376

Group type: EXPERIMENTAL
Intervention: Jiaotai pill (JTP) plus fluoxetine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoxetine alone
Number of subjects: 40
Study: 36034810

Group type: EXPERIMENTAL
Intervention: Jiedu Tongluo Tiaogan Formula (JTTF) + conventional basic treatment
Number of subjects: 98

Group type: COMPARATOR
Intervention: Conventional basic treatment
Number of subjects: 98
Study: 33169409

Group type: EXPERIMENTAL
Intervention: cilofexor/firsocostat
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: cilofexor/selonsertib
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: firsocostat/selonsertib
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: firsocostat
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: cilofexor
Number of subjects: 392

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 392
Study: 34083113

Group type: EXPERIMENTAL
Intervention: Bisoprolol patch therapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Surgery time of 250 min or more
Number of subjects: 240
Study: 33000587

Group type: EXPERIMENTAL
Intervention: Acupoint therapy combined with spine pinching
Number of subjects: 132

Group type: COMPARATOR
Intervention: Tibolone therapy alone
Number of subjects: 132
Study: 36189824

Group type: EXPERIMENTAL
Intervention: Pilates training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Aqua-Pilates training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study: 33516195

Group type: EXPERIMENTAL
Intervention: Geriatric intervention and exercise (preoperative CGA, perioperative geriatric in‐ward review, postoperative follow‐up, resistance exercise program twice/week for 2+12 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Geriatric intervention and exercise
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 100
Study: 32566276

Group type: EXPERIMENTAL
Intervention: Laparoscopic banded sleeve gastrectomy (LBSG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 50
Study: 33728742

Group type: EXPERIMENTAL
Intervention: Strategy training in addition to usual care
Number of subjects: 275

Group type: COMPARATOR
Intervention: Control condition in addition to usual care
Number of subjects: 275
Study: 33574145

Group type: EXPERIMENTAL
Intervention: Concussion Essentials (CE), a multimodal, interdisciplinary delivered, symptom‐tailored treatment involving physiotherapy, psychology, and education, 1 hour per week for up to 8 weeks or until pPCS resolve.
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Concussion Essentials (CE)
Number of subjects: 216
Study: 32695314

Group type: EXPERIMENTAL
Intervention: TFESI plus CESI (TC group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: TFESI alone (T group)
Number of subjects: 54
Study: 35674176

Group type: EXPERIMENTAL
Intervention: Tablet technology and animated videos
Number of subjects: 26
Study: 32361934

Group type: EXPERIMENTAL
Intervention: Medium-dose HSYAI (50 mg/d)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: High-dose HSYAI (70 mg/d)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Control group (Dengzhan Xixin Injection, 30 mL/d)
Number of subjects: 266
Study: 34783404

Group type: EXPERIMENTAL
Intervention: SCR + aPDT
Number of subjects: 64

Group type: COMPARATOR
Intervention: SCR
Number of subjects: 64
Study: 34558154

Group type: EXPERIMENTAL
Intervention: Cone-beam computed tomography (CBCT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 3D CBCT-based planning software
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Periapical radiographs
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study: 35970781

Group type: EXPERIMENTAL
Intervention: Three-dimensional visualized model of impacted tooth
Number of subjects: 41
Study: 32085626

Group type: EXPERIMENTAL
Intervention: 8-week whole-body vibration (WBV) training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo group performing the same protocol without vibration
Number of subjects: 90
Study: 35088617

Group type: EXPERIMENTAL
Intervention: Participant-driven group education plus standard information
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard information alone
Number of subjects: 138
Study: 33310533

Group type: EXPERIMENTAL
Intervention: Preventive antiepileptic treatment (Vigabatrin preferred for patients younger than two years old)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: EEG monitoring (including video EEG)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Vigabatrin for focal and generalized seizures
Number of subjects: 61
Study: 32365090

Group type: EXPERIMENTAL
Intervention: ggmix (general penalized linear mixed model)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-stage approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Principal component adjustment
Number of subjects: 0
Study: 33599984

Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Levonorgestrel implant
Number of subjects: 740

Group type: COMPARATOR
Intervention: OCP
Number of subjects: 740
Study: 32449907

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 35
Study: 36262968

Group type: EXPERIMENTAL
Intervention: Rhus coriaria (3 pills daily for 6 days)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Triamcinolone (oral paste, 3 times a day for 6 days)
Number of subjects: 22
Study: 34014258

Group type: EXPERIMENTAL
Intervention: Auditory stimulation with music
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Auditory stimulation with noise
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ambient noise insulation with masking earplugs
Number of subjects: 104

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 104
Study: 32607084

Group type: EXPERIMENTAL
Intervention: Kratom
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 32579051

Group type: EXPERIMENTAL
Intervention: Static stretching (four, 15‐s straight‐leg raise static stretches)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 15
Study: 33487031

Group type: EXPERIMENTAL
Intervention: LHW-led physical activity counselling program (8-week, once weekly)
Number of subjects: 49
Study: 32204895

Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Ketogenic (VLCK) diet
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard Low-Calorie (LC) diet
Number of subjects: 46
Study: 35110313

Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural therapy with virtual reality exposure (CBT-in virtuo)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Group cognitive behavioural therapy with in vivo exposure (CBT-in vivo)
Number of subjects: 302
Study: 34798604

Group type: EXPERIMENTAL
Intervention: Glibenclamide (5 mg oral for 21 days)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 78
Study: 32635650

Group type: EXPERIMENTAL
Intervention: Mindfulness exercises, self-monitoring, and mood tracking
Number of subjects: 143
Study: 34154926

Group type: EXPERIMENTAL
Intervention: Atezolizumab with trastuzumab/pertuzumab and docetaxel (mBC)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Atezolizumab/T-DM1 (mBC)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Atezolizumab with trastuzumab/pertuzumab or T-DM1 (eBC)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Trastuzumab/pertuzumab (eBC)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: T-DM1 (eBC)
Number of subjects: 73
Study: 33450164

Group type: EXPERIMENTAL
Intervention: Topical ocular reproxalap (0.1% ophthalmic solution, 0.5% ophthalmic solution, and 0.5% lipid ophthalmic solution)
Number of subjects: 51
Study: 32800304

Group type: EXPERIMENTAL
Intervention: Body Dysmorphic Disorder (BDD) group
Number of subjects: 94

Group type: COMPARATOR
Intervention: Nonpsychiatric controls
Number of subjects: 94
Study: 34561362

Group type: EXPERIMENTAL
Intervention: Bioniko
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Kitaro
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: SimulEYE
Number of subjects: 7
Study: 35372979

Group type: EXPERIMENTAL
Intervention: Tenapanor 30 mg twice daily for 26 weeks
Number of subjects: 564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Tenapanor
Number of subjects: 564

Group type: COMPARATOR
Intervention: Sevelamer carbonate
Number of subjects: 564
Study: 33462955

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35974290

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 2 weeks (Q2W)
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Alirocumab 300 mg every 4 weeks (Q4W)
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Co-administration of statins with alirocumab
Number of subjects: 527
Study: 33639516

Group type: EXPERIMENTAL
Intervention: Reiki treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 48
Study: 32392700

Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 120
Study: 36402794

Group type: EXPERIMENTAL
Intervention: Proximal femoral nail anti-rotation (PFNA) fixation
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Integrated Scoring System (ISSI)
Number of subjects: 450
Study: 36352475

Group type: EXPERIMENTAL
Intervention: Five complementary strategies: feedback and transparency
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Five complementary strategies: intervention sustainability
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Five complementary strategies: clinical practice guideline adherence
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Five complementary strategies: productive partnerships
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Five complementary strategies: whole-of-team approach
Number of subjects: 26
Study: 32711519

Group type: EXPERIMENTAL
Intervention: Avenanthramide (AVA) supplementation (206 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (0 mg/kg)
Number of subjects: 24
Study: 35722469

Group type: EXPERIMENTAL
Intervention: Propofol/Esketamine
Number of subjects: 238

Group type: COMPARATOR
Intervention: Propofol/Fentanyl
Number of subjects: 238
Study: 32497714

Group type: EXPERIMENTAL
Intervention: Acupressure applied on SP6, SP10, ST36, and LI11 points
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham control (ineffective points)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Negative control (routine care)
Number of subjects: 90
Study: 35232402

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 45
Study: 32369446

Group type: EXPERIMENTAL
Intervention: neoadjuvant metformin, debulking surgery, and adjuvant chemotherapy plus metformin
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy and metformin, interval debulking surgery, and adjuvant chemotherapy plus metformin
Number of subjects: 38
Study: 35443107

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (eating only between 8:00 a.m. and 4:00 p.m.) with calorie restriction
Number of subjects: 139

Group type: COMPARATOR
Intervention: Daily calorie restriction alone
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Number of subjects: 139

Group type: COMPARATOR
Intervention: Time-restricted eating and daily calorie restriction
Number of subjects: 139
Study: 34140351

Group type: EXPERIMENTAL
Intervention: Vocal music listening
Number of subjects: 38

Group type: COMPARATOR
Intervention: Audiobooks
Number of subjects: 38
Study: 36192769

Group type: EXPERIMENTAL
Intervention: Family Support for Health Action (FAM-ACT)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Individual patient-focused DSMES (I-DSMES)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: FAM-ACT
Number of subjects: 268
Study: 34820354

Group type: EXPERIMENTAL
Intervention: Brochure group
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Instagram group
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Online interactive educational workshop group
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (placebo intervention)
Number of subjects: 155
Study: 32729887

Group type: EXPERIMENTAL
Intervention: Mx protocol (annual mammography and clinical breast examination)
Number of subjects: 10000000

Group type: EXPERIMENTAL
Intervention: MRI protocol (annual MRI and clinical breast examination plus biennial mammography)
Number of subjects: 10000000

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging every 18 months between ages 35 and 60 years
Number of subjects: 10000000

Group type: EXPERIMENTAL
Intervention: Annual screening alternating MRI and mammography between ages 35 and 60 years
Number of subjects: 10000000
Study: 33436106

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) - 6 sessions at -130°C over 6 weeks
Number of subjects: 23